Table 1.
Characteristics of CKDp, quoted as the median (interquartile range) and the number (%)
| Characteristics | Overall study population | Non-transplant CKDps | KTRs | P-value |
|---|---|---|---|---|
| N | 363 | 226 | 137 | |
| CF-PWV (KTRs, mo. 12) | 10.59 (9.00–12.65) | 11.00 (9.00–13.00) | 10.09 (9.00–11.49) | 0.008 |
| CF-PWV (KTRs, mo. 3) | 11.00 (9.00–13.00) | 11.00 (9.00–13.00) | 10.50 (9.23–12.14) | 0.242 |
| Quantitative data | ||||
| Age (years) | 54.90 (44.10–63.15) | 56.80 (42.60–65.12) | 54.00 (45.00–61.00) | 0.228 |
| mGFR at inclusion (mL/min/1.73 m2) | 52.10 (36.60–66.18) | 47.75 (33.82–68.80) | 54.55 (44.37–64.24) | 0.067 |
| BMI (kg/m2) | 25.22 (22.22–29.11) | 25.22 (21.88–29.31) | 25.40 (22.72–28.68) | 0.678 |
| Systolic BP (mmHg) | 130 (118–141) | 130 (118–143) | 130 (120–140) | 0.936 |
| Diastolic BP (mmHg) | 73 (65–80) | 72 (64–80) | 73 (66–80) | 0.541 |
| MBP (mmHg) | 92 (83–100) | 90 (83–100) | 93 (84–100) | 0.682 |
| Renal parameters | ||||
| Aetiology of kidney disease, n (%) | 0.264 | |||
| Diabetic | 36 (9.9) | 26 (11.5) | 10 (7.3) | |
| Other | 327 (90.1) | 200 (88.5) | 127 (92.7) | |
| Urinary protein:creatinine ratio (mg/mmol) | 24 (11–69) | 29 (14–79) | 18 (9–53) | 0.001 |
| Urinary albumin:creatinine ratio (mg/mmol) | 6 (2–32) | 7 (2–37) | 4 (2–19) | 0.030 |
| Conventional cardiovascular risk factors, n (%) | ||||
| Sex (male) | 216 (59.5) | 130 (57.5) | 86 (62.8) | 0.380 |
| Diabetes | 108 (29.8) | 73 (32.3) | 35 (25.5) | 0.213 |
| Hypertension | 331 (91.2) | 204 (90.3) | 127 (92.7) | 0.547 |
| Current smoking | 45 (12.4) | 31 (13.7) | 14 (10.2) | 0.327 |
| Medications, n (%) | ||||
| Diuretics | 113 (31.1) | 95 (42.0) | 18 (13.1) | <0.001 |
| Beta-adrenergic blockers | 108 (29.8) | 51 (22.6) | 57 (41.6) | <0.001 |
| Calcium channel blockers | 158 (43.5) | 76 (33.6) | 82 (59.9) | <0.001 |
| ACE inhibitors and/or ARBs | 250 (68.9) | 179 (79.2) | 71 (51.8) | <0.001 |
| Statins | 138 (38.0) | 87 (38.5) | 51 (37.2) | 0.897 |
| Biochemical CKD-MBD parameters | ||||
| Serum calcium (mmol/L) | 2.31 (2.23–2.41) | 2.28 (2.20–2.36) | 2.40 (2.29–2.48) | <0.001 |
| Blood ionized serum calcium (mmol/L) | 1.21 (1.17–1.25) | 1.20 (1.17–1.23) | 1.24 (1.20–1.27) | <0.001 |
| Serum magnesium (mmol/L) | 0.78 (0.71–0.85) | 0.81 (0.75–0.87) | 0.73 (0.65–0.79) | <0.001 |
| Serum phosphate (mmol/L) | 1.02 (0.20) | 1.03 (0.92–1.19) | 0.98 (0.85–1.09) | 0.001 |
| Serum PTH (pg/mL) | 52.00 (34.00–90.00) | 48.50 (29.00–91.50) | 57.00 (39.00–89.00) | 0.031 |
| Serum 25(OH)D (ng/mL) | 19.00 (13.00–27.50) | 18.00 (12.00–28.00) | 19.00 (14.00–26.30) | 0.334 |
| Serum 1,25(OH)2D (pg/mL) | 34.00 (24.00–49.00) | 29.00 (20.25–41.00) | 46.00 (33.00–63.00) | <0.001 |
| Urinary calcium/creatinine (mM/mM) | 0.06 (0.02–0.15) | 0.04 (0.01–0.11) | 0.10 (0.04–0.17) | <0.001 |
| Serum bone alkaline phosphatase (µg/L) | 12.10 (8.80–17.98) | 11.60 (8.80–16.60) | 13.60 (9.05–19.85) | 0.031 |
Data include non-transplant CKDps from the NephroTest cohort and KTRs from the TransplanTest cohort. Values are presented as median (IQR) unless stated otherwise.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CKD-MBD, CKD-associated mineral and bone disorder; mo., months.